JP2005525784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525784A5 JP2005525784A5 JP2003521781A JP2003521781A JP2005525784A5 JP 2005525784 A5 JP2005525784 A5 JP 2005525784A5 JP 2003521781 A JP2003521781 A JP 2003521781A JP 2003521781 A JP2003521781 A JP 2003521781A JP 2005525784 A5 JP2005525784 A5 JP 2005525784A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- hybrid protein
- composition
- protein
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims 31
- 108090000623 proteins and genes Proteins 0.000 claims 31
- 239000000203 mixture Substances 0.000 claims 19
- 108010050904 Interferons Proteins 0.000 claims 14
- 102000014150 Interferons Human genes 0.000 claims 14
- 210000004899 c-terminal region Anatomy 0.000 claims 8
- 108700027921 interferon tau Proteins 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 5
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 230000003013 cytotoxicity Effects 0.000 claims 4
- 231100000135 cytotoxicity Toxicity 0.000 claims 4
- 108010014726 Interferon Type I Proteins 0.000 claims 3
- 102000002227 Interferon Type I Human genes 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000000840 anti-viral effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 claims 1
- 101710106107 Interferon alpha-D Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31186601P | 2001-08-12 | 2001-08-12 | |
| PCT/US2002/025691 WO2003016472A2 (en) | 2001-08-12 | 2002-08-12 | Hybrid interferon/interferon tau proteins, compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525784A JP2005525784A (ja) | 2005-09-02 |
| JP2005525784A5 true JP2005525784A5 (https=) | 2006-01-05 |
Family
ID=23208847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003521781A Pending JP2005525784A (ja) | 2001-08-12 | 2002-08-12 | ハイブリッドインターフェロン／インターフェロンτタンパク質、組成物、および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7232563B2 (https=) |
| EP (1) | EP1425409A4 (https=) |
| JP (1) | JP2005525784A (https=) |
| KR (1) | KR20040022244A (https=) |
| CN (1) | CN1568369A (https=) |
| CA (1) | CA2454860A1 (https=) |
| WO (1) | WO2003016472A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US7083782B2 (en) * | 2000-07-19 | 2006-08-01 | Pepgen Corporation | Method of treatment using interferon-tau |
| US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
| US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
| US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
| US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| EP2327724A3 (en) | 2004-02-02 | 2011-07-27 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| AU2008201682B2 (en) * | 2004-02-02 | 2011-02-24 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
| US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
| US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| US7695710B2 (en) * | 2005-06-20 | 2010-04-13 | Pepgen Corporation | Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs |
| KR20080037656A (ko) * | 2005-06-20 | 2008-04-30 | 펩젠 코포레이션 | 저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라 |
| US20070243163A1 (en) * | 2006-02-17 | 2007-10-18 | Chih-Ping Liu | Respiratory tract delivery of interferon-tau |
| HRP20160855T1 (hr) | 2008-02-08 | 2016-09-23 | Medimmune, Llc | Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda |
| US11292823B2 (en) | 2017-05-01 | 2022-04-05 | Rutgers, The State University Of New Jersey | Type I and type III interferon fusion molecules and methods for use thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2016015B (en) * | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
| US4460574A (en) * | 1980-06-16 | 1984-07-17 | Yabrov Alexander A | Prophylaxis or treatment of interferon-sensitive diseases |
| US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4507281A (en) * | 1981-10-13 | 1985-03-26 | Exovir, Inc. | Interferon-containing compositions |
| WO1983002461A1 (en) * | 1982-01-19 | 1983-07-21 | Cetus Corp | Multiclass hybrid interferons |
| US4456784A (en) * | 1982-03-26 | 1984-06-26 | Eaton Corporation | Conduit sealing connector |
| US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
| EP0146903A3 (en) | 1983-12-19 | 1987-07-22 | Schering Corporation | Production of a vector encoding a novel hybrid interferon species |
| US4636383A (en) * | 1984-08-29 | 1987-01-13 | Schering Corporation | Interferon-cyclaradine combination |
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| US4895743A (en) * | 1985-04-30 | 1990-01-23 | Phillips Petroleum Company | Blow molded article |
| DE3607835A1 (de) * | 1986-03-10 | 1987-09-24 | Boehringer Ingelheim Int | Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung |
| US4846782A (en) * | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
| ZA878295B (en) * | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
| EP0367063A1 (en) | 1988-10-26 | 1990-05-09 | The Curators Of The University Of Missouri | Isolation and cloning of complementary DNA for gene coding of bovine trophoblast protein-1 |
| US4997646A (en) * | 1989-02-23 | 1991-03-05 | University Of Florida Research Foundation, Inc. | Use of interferons of the alpha family to enhance fertility in mammals |
| AU5183490A (en) | 1989-03-02 | 1990-09-26 | University Of Florida | Composition for the inhibition of tumors and for the non-cytotoxic inhibition of replication of viruses |
| US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
| US5540923A (en) | 1991-12-06 | 1996-07-30 | Landsforeningen Til Kraeftens Bekaemplse | Interferon proteins |
| AU5369794A (en) | 1992-10-23 | 1994-05-24 | Unichema Chemie Bv | Condensates of metal compound and polyhydroxy compound and vinyl halide polymers stabilised therewith |
| CN1090510A (zh) | 1992-10-30 | 1994-08-10 | 佛罗里达大学 | 干扰素-τ组成物及其用途 |
| US5939286A (en) * | 1995-05-10 | 1999-08-17 | University Of Florida | Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them |
| EP0904373A1 (en) * | 1996-03-14 | 1999-03-31 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
| US6204022B1 (en) | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
-
2002
- 2002-08-12 WO PCT/US2002/025691 patent/WO2003016472A2/en not_active Ceased
- 2002-08-12 KR KR10-2004-7002138A patent/KR20040022244A/ko not_active Ceased
- 2002-08-12 CA CA002454860A patent/CA2454860A1/en not_active Abandoned
- 2002-08-12 US US10/218,338 patent/US7232563B2/en not_active Expired - Fee Related
- 2002-08-12 EP EP02752824A patent/EP1425409A4/en not_active Withdrawn
- 2002-08-12 JP JP2003521781A patent/JP2005525784A/ja active Pending
- 2002-08-12 CN CNA028199375A patent/CN1568369A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525784A5 (https=) | ||
| JP2003530839A5 (https=) | ||
| JP2001520238A5 (https=) | ||
| CA2308116A1 (en) | Low-toxicity human interferon-alpha analog | |
| JP5907970B2 (ja) | インターロイキン−２２のウイルス性肝炎の治療における応用 | |
| JP2003246750A (ja) | 持続的低用量サイトカイン注入治療 | |
| JP2010503396A5 (https=) | ||
| JP2007531741A5 (https=) | ||
| US7083782B2 (en) | Method of treatment using interferon-tau | |
| WO2007098106A2 (en) | Respiratory tract delivery of interferon-tau | |
| JP2005527547A5 (https=) | ||
| Alexenko et al. | The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| US20040247565A1 (en) | Method of treatment using interferon-tau | |
| JP2001526242A5 (https=) | ||
| CN101463089B (zh) | 人血清白蛋白-干扰素融合蛋白及其编码基因与应用 | |
| Sirbu et al. | History of interferon treatments in multiple sclerosis-60 years of progress | |
| WO2003061728B1 (en) | Oral administration of interferon-tau | |
| US20030026779A1 (en) | Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc | |
| US20070237743A1 (en) | Combination therapies using low-toxicity, long-circulating human interferon-alpha analogs | |
| US11292823B2 (en) | Type I and type III interferon fusion molecules and methods for use thereof | |
| US20060078942A1 (en) | Method of treatment using interferon-tau | |
| US20060134750A1 (en) | Method of treatment using interferon-tau | |
| EP1933861B1 (en) | Method for treating or preventing multi-organ failure | |
| US20050002902A1 (en) | Hybrid with interferon-alpha and an immunoglobulin Fc for treatment of tumors and viral infections |